Highlights Hangzhou Tigermed Consulting Co., Ltd

Equities

300347

CNE100001KV8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 2026-03-06			5-day change	1st Jan Change
57.37 ^CNY	+1.06%		-3.81%	+1.18%

Mar. 03	Frontage Unit Acquires Research Lab Firm from Tigermed Consulting Unit	MT
Feb. 13	Beijing Trimmune Biotech Co., Ltd. announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd	CI

Highlights

Mar. 03	Frontage Unit Acquires Research Lab Firm from Tigermed Consulting Unit	MT
Jan. 29	Tigermed Consulting Forecasts Upto 204% Jump in 2025 Profit; Shares Rise 8%	MT
Jan. 29	Hangzhou Tigermed Consulting sees 2025 net profit up 105-204% Y/Y	RE
Jan. 29	Tigermed Consulting Expects Up to 204% Surge in 2025 Profit	MT
25-10-28	Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-28	Tigermed Consulting's Q3 Profit Soars 99%	MT
25-10-28	Hangzhou Tigermed Consulting posts qtrly revenue RMB1.78 billion	RE
25-10-10	Hangzhou Tigermed Consulting to Sell Research Lab Firm to Frontage Unit	MT
25-08-29	Hangzhou Tigermed Consulting's Attributable Profit Slides 22% in H1	MT
25-08-28	Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-29	Tigermed completes acquisition of Japanese CRO Micron	RE
25-07-29	Tigermed completes acquisition of Japanese CRO Micron	RE
25-07-28	Hangzhou Tigermed Consulting says acquisition of partial equity interest in Micron in Japan by unit	RE
25-07-18	Hangzhou Tigermed Consulting Sells 3.4% Stake in LaNova Medicines for $34 Million	MT
25-05-30	Hangzhou Tigermed Consulting Co., Ltd Declares Final Dividend for the Year Ended December 31, 2024, Payable on 11 July 2025	CI
25-04-30	Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced on May 24, 2024.	CI
25-04-29	Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback announced on May 24, 2024, has closed with 9,806,300 shares, representing 1.14% for CNY 500.12 million.	CI
25-04-28	Tigermed Consulting's Q1 Profit Slides 30%	MT
25-04-28	Hangzhou Tigermed's Q1 Net Profit Down 29.6% Y/Y	RE
25-04-28	Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-02	Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced on May 24, 2024.	CI
25-03-28	Hangzhou Tigermed Consulting 2024 Profit Decreases 80%; Shares Slide	MT
25-03-27	Hangzhou Tigermed Consulting Co., Ltd Proposes Final Dividend for the Year Ended 31 December 2024, Payable on 31 July 2025	CI
25-03-27	Tigermed Reports Full Year 2024 Results	RE
25-03-27	Tigermed Says 2024 Net Profit Down 80.0% Y/Y	RE